GlaxoSmithKline's new CEO is assembling a "dream team" to rebuild the big pharma's R&D pipeline with an emphasis on building in oncology. Walmsley outlined her strategy at J.P. Morgan, while Oncology Therapy Area Head Axel Hoos provided more details in an interview.
GlaxoSmithKline PLC CEO Emma Walmsley's growth strategy for the big pharma calls for reversing course to reprioritize pharmaceutical R&D and innovation, with a particularly notable focus in a new potential growth area, oncology. Walmsley believes GSK can be a power player in the competitive field of oncology, where it lags rivals by a long shot.
Walmsley is assembling a "dream team" to rebuild GSK's pharmaceutical pipeline, and the appointment of Hal Barron, a highly-regarded cancer...
The CEO of South Korean biotech shares how his company was able to reach a partnership with Rani so quickly and why it is confident in its GLP-1/GLP-2 dual agonist for obesity and diabetes, despite recent disappointing clinical results for its sole rival.
The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.
Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.
An academic study of GLP-1 agonist showed promise in patients with the painful skin condition but with no signs that the Danish drugmaker will pursue the indication, smaller players in the space may be interested.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
